Biocon shares surge over 4% after Malaysia unit gets clearance from the USFDA

Biocon shares rose 4.5% to an intraday high of Rs 376.95 on the BSE on Monday, January 13, after the U.S. Food and Drug Administration (FDA) granted Biocon Biologics' insulin facilities in Johor Bahru, Malaysia, a Voluntary Action Indicated (VAI) classification.